Lantheus Holdings, Inc. (LNTH)
Lantheus Holdings: Q3 Results Were Good But Market Overreacted
Lantheus, with a strong pharmaceutical portfolio and double-digit growth, fell 20% post-Q3 2024 due to expected weak Q4 EPS from temporary expenses. Key products Pylarify and Definity enhance diagnostic imaging for prostate cancer and heart conditions, respectively, with significant market potential and government support. Despite a conservative Q4 outlook, Lantheus' forward P/E of 13 and projected 15% annual revenue growth present an attractive buying opportunity.
Lantheus Holdings, Inc. (LNTH) Q3 2024 Earnings Call Transcript
Lantheus Holdings, Inc. (NASDAQ:LNTH ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Mark Kinarney - VP of IR Brian Markison - CEO Paul Blanchfield - President Bob Marshall - CFO Jeff Humphrey - Chief Medical Officer Conference Call Participants Roanna Ruiz - Leerink Partners Anthony Petrone - Mizuho Group Richard Newitter - Truist Securities Matt Taylor - Jefferies Larry Solow - CJS Securities Tara Bancroft - TD Cowen Yuan Zhi - B. Riley Kemp Dolliver - Brookline Capital Markets Justin Walsh - Jones Trading Andy Hsieh - William Blair Ed Ridley-Day - Redburn Atlantic Operator Good morning.
Lantheus: A Radiopharmaceutical Powerhouse In The Making (Q2 2024 Update)
PYLARIFY is the leading PSMA PET imaging agent, on track to surpass $1 billion in sales by 2024, driving significant revenue growth for Lantheus Holdings, Inc. Lantheus is heavily investing in its oncology and Alzheimer's diagnostics pipeline, positioning itself for substantial long-term growth despite short-term profit impacts. With robust free cash flow, a solid balance sheet, and potential for significant EPS growth, Lantheus Holdings is undervalued and could reach $250 per share by 2028.
Why Lantheus Holdings Stock Is Skyrocketing Today
Medicare will likely soon change how it pays for diagnostic radiopharmaceuticals. Lantheus should be a big winner from this reimbursement change.
Lantheus Stock Gets A Radioactive Surge On Medicare Proposal
Lantheus stock rocketed to a 13-month high Wednesday after a Medicare proposal suggested hiking the reimbursement rate for some diagnostics.
Why Lantheus Holdings (LNTH) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Lantheus (LNTH) Gains 33.3% YTD: What's Driving the Stock?
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
Lantheus Holdings (LNTH) Stock Drops Despite Market Gains: Important Facts to Note
In the most recent trading session, Lantheus Holdings (LNTH) closed at $79.28, indicating a -0.78% shift from the previous trading day.
Lantheus Holdings (LNTH) Upgraded to Strong Buy: What Does It Mean for the Stock?
Lantheus Holdings (LNTH) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for May 31st
MNSO, LNTH and LXFR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 31, 2023.
Here's Why You Should Add Lantheus (LNTH) to Your Portfolio Now
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
Are Medical Stocks Lagging Lantheus (LNTH) This Year?
Here is how Lantheus Holdings (LNTH) and Agios Pharmaceuticals (AGIO) have performed compared to their sector so far this year.
